WHAT IS OXYMORPHONE AND HOW DOES IT WORK?
Oxymorphone is a narcotic pain reliever used to treat moderate-to-severe pain. The extended-release form is for around-the-clock treatment of pain.
Oxymorphone is available under the following different brand names: Opana, and Opana ER.
Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death
Assess each patient’s risk prior to prescribing and monitor all patients regularly for the development of these behaviors or conditions
Also effective for relief of anxiety in patients with shortness of breath (dyspnea) associated with pulmonary edema secondary to acute left ventricular dysfunction
- 1-1.5 mg intramuscularly/subcutaneously (IM/SC) every 4-6 hours as needed
- Analgesia during labor: 0.5-1 mg IM
- Intravenously (IV): 0.5 mg, increased as needed
- Immediate-release tablets showed for acute moderate-to-severe pain where opioid use is appropriate
- Opioid-naïve patients (immediate-release): 10-20 mg orally every 4-6 hours as needed initially, then titrated as warranted (may start with 5-mg increments)
- Conversion from intravenous (IV) oxymorphone to oral: The absolute bioavailability of orally is approximately 10%, therefore conversion from 1 mg IV every 4-6 hours is equipotent to 10 mg orally every 4-6 hours
- Elderly patients or those with renal or hepatic impairment: 5 mg orally every 4-6 hours initially
Chronic Severe Pain
Extended-release is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
Opioid-naïve patients (extended-release): 5 mg orally every 12 hours initially, then titrated in increments of 5-10 mg every 12 hours every 3-7 days to level that provide adequate analgesia and minimizes side effects
Conversion from intravenous (IV) oxymorphone to extended-release oral: The absolute oral bioavailability of Opana ER is approximately 10%, therefore conversion from 1 mg IV every 6 hours (4 mg/day) is equipotent to 20 mg orally every 12 hours (40 mg/day)
Conversion from oral opioids to Opana ER: See prescribing information
- Use of higher starting doses in patients who are not opioid tolerant may cause fatal respiratory depression
- Patients who are opioid tolerant are those receiving, for 1 week or longer, at least 60 mg/day orally morphine, 25 mcg/hour transdermal fentanyl, 30 mg/day orally oxycodone, 8 mg/day orally hydromorphone, 25 mg/day orally oxymorphone, or an equianalgesic dose of another opioid
- Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve for patients whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain
- showed Not showed as a as needed analgesic